Viral Vectors for Gene Therapy: Translational and Clinical Outlook

Annual Review of Biomedical Engineering

Volumn 17, Issue , 2015, Pages 63-89

  Kotterman, Melissa A ^a   Chalberg, Thomas W ^b   Schaffer, David V ^a,c  

^a 4D Molecular Therapeutics   (United States)

^b Avalanche Biotechnologies   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adeno Associated virus; Adenovirus; Genotoxicity; Lentivirus; Retrovirus; Vector engineering

Indexed keywords

DISEASE CONTROL; GENES; VECTORS; VIRUSES;

ADENO-ASSOCIATED VIRUS; ADENOVIRUS; GENOTOXICITIES; LENTIVIRUS; RETROVIRUS;

GENE THERAPY;

ADENOVIRUS VECTOR; HERPES SIMPLEX VIRUS VECTOR; HERPESVIRUS VECTOR; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; POXVIRUS VECTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; BIOENGINEERING; EX VIVO GENE TRANSFER; GENE TARGETING; GENOTOXICITY; HISTORY OF MEDICINE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VIVO GENE TRANSFER; LENTIVIRINAE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS DNA CELL DNA INTERACTION; CLINICAL TRIAL (TOPIC); DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; IMMUNOLOGIC DEFICIENCY SYNDROMES; PROCEDURES; RETROVIRIDAE; TRANSLATIONAL RESEARCH;

CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LENTIVIRUS; RETROVIRIDAE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84949509925     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-071813-104938     Document Type: Review

References (152)

1. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, et al. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245(4922):1059-65
2. Riordan JR, Rommens JM,Kerem B, Alon N, Rozmahel R, et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922):1066-73
3. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, et al. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245(4922):1073-80
4. Macdonald M. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6):971-83
5. Mann R, Mulligan RC, Baltimore D. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33(1):153-59
6. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, et al. 1995. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270(5235):475-80
7. Bordignon C,Notarangelo LD,Nobili N, Ferrari G, Casorati G, et al. 1995. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA immunodeficient patients. Science 270(5235):470-75
8. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, et al. 1995. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat. Med. 1(10):1017-23
9. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288(5466):669-72
10. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296(5577):2410-13
11. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, et al. 2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360(5):447-58
12. Kohn DB, Candotti F. 2009. Gene therapy fulfilling its promise. N. Engl. J. Med. 360(5):518-21
13. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, et al. 2003. LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644):415-19
14. Wilson JM. 2009. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol. Genet. Metab. 96(4):151-57
15. Gabrilovich DI. 2006. INGN 201 (Advexin): Adenoviral p53 gene therapy for cancer. Expert Opin. Biol. Ther. 6(8):823-32
16. Barquinero J, Eixarch H, Pérez-Melgosa M. 2004. Retroviral vectors: new applications for an old tool. Gene Ther. 11(Suppl. 1):S3-9
17. Rohdewohld H, Weiher H, Reik W, Jaenisch R, BreindlM. 1987. Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. J. Virol. 61(2):336-43
18. Vijaya S, Steffen DL, Robinson HL. 1986. Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J. Virol. 60(2):683-92
19. Cattoglio C, FacchiniG, Sartori D, Antonelli A, Miccio A, et al. 2007. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110(6):1770-78
20. Cattoglio C, Pellin D, Rizzi E, Maruggi G, Corti G, et al. 2010. High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 116(25):5507-17
21. Roth SL,Malani N, Bushman FD. 2011. Gammaretroviral integration into nucleosomal target DNA in vivo. J. Virol. 85(14):7393-401
22. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, et al. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Investig. 118(9):3132-42
23. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, et al. 2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Investig. 118(9):3143-50
24. Woods N-B, Bottero V, Schmidt M, von Kalle C, Verma IM. 2006. Gene therapy: therapeutic gene causing lymphoma. Nature 440(7088):1123
25. Modlich U, Bohne J, Schmidt M, von Kalle C, Knöss S, et al. 2006. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108(8):2545-53
26. Cavazza A, Cocchiarella F, Bartholomae C, Schmidt M, Pincelli C, et al. 2013. Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes. Gene Ther. 20(9):949-57
27. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259):263-67
28. Escors D, Breckpot K. 2010. Lentiviral vectors in gene therapy: their current status and future potential. Arch. Immunol. Ther. Exp. (Warsz) 58(2):107-19
29. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72(11):8463-71
30. Schröder ARW, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110(4):521-29
31. Wu X, Li Y, Crise B, Burgess SM. 2003. Transcription start regions in the human genome are favored targets for MLV integration. Science 300(5626):1749-51
32. Mitchell RS, Beitzel BF, Schroder ARW, Shinn P, Chen H, et al. 2004. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLOS Biol. 2(8):E234
33. Barr SD, Ciuffi A, Leipzig J, Shinn P, Ecker JR, Bushman FD. 2006. HIV integration site selection: targeting in macrophages and the effects of different routes of viral entry. Mol. Ther. 14(2):218-25
34. Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD. 2007. HIV integration site selection: Analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 17(8):1186-94
35. Wang GP, Levine BL, Binder GK, Berry CC, Malani N, et al. 2009. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol. Ther. 17(5):844-50
36. Lewinski MK, Yamashita M, EmermanM,Ciuffi A, Marshall H, et al. 2006. RetroviralDNAintegration: viral and cellular determinants of target-site selection. PLOS Pathog. 2(6):e60
37. Cherepanov P, Ambrosio ALB, Rahman S, Ellenberger T, Engelman A. 2005. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. PNAS 102(48):17308-13
38. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, et al. 2003. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278(1):372-81
39. Emiliani S,Mousnier A, Busschots K, Maroun M, Van Maele B, et al. 2005. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J. Biol. Chem. 280(27):25517-23
40. LlanoM, Saenz DT,Meehan A, Wongthida P, PeretzM, et al. 2006. An essential role for LEDGF/p75 in HIV integration. Science 314(5798):461-64
41. De Rijck J, Bartholomeeusen K, Ceulemans H, Debyser Z, Gijsbers R. 2010. High-resolution profiling of the LEDGF/p75 chromatin interaction in the encode region. Nucleic Acids Res. 38(18):6135-47
42. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, et al. 2005. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 11(12):1287-89
43. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, et al. 2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24(6):687-96
44. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, et al. 2009. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Investig. 119(4):964-75
45. Wagner TA, McLaughlin S, Garg K, Cheung CYK, Larsen BB, et al. 2014. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345(6196):570-73
46. Cavazzana-Calvo M, Payen E, Negre O,Wang G, Hehir K, et al. 2010. Transfusion independence and HMGA2 activation after gene therapy of human-thalassaemia. Nature 467(7313):318-22
47. RonenK,Negre O, Roth S, Colomb C, MalaniN, et al. 2011. Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat-thalassemia. Mol. Ther. 19(7):1273-86
48. DePolo NJ, Reed JD, Sheridan PL, Townsend K, Sauter SL, et al. 2000. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol. Ther. 2(3):218-22
49. Knipe DM, Howley PM. 2007. Fields' Virology. Philadelphia, PA: LippincottWilliams & Wilkins
50. Sonntag F, Schmidt K, Kleinschmidt JA. 2010. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. PNAS 107(22):10220-25
51. Sonntag F, Köther K, Schmidt K, Weghofer M, Raupp C, et al. 2011. The assembly-Activating protein promotes capsid assembly of different adeno-Associated virus serotypes. J. Virol. 85(23):12686-97
52. Flotte TR. 2004. Gene therapy progress and prospects: recombinant adeno-Associated virus (rAAV) vectors. Gene Ther. 11(10):805-10
53. Schaffer DV, Koerber JT, Lim K. 2008. Molecular engineering of viral gene delivery vehicles. Annu. Rev. Biomed. Eng. 10:169-94
54. Wu Z, Asokan A, Samulski RJ. 2006. Adeno-Associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14(3):316-27
55. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, et al. 2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12(3):342-47
56. Mease PJ, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, et al. 2009. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor antagonist gene in inflammatory arthritis: A phase 1 dose-escalation safety and tolerability study. Ann. Rheum. Dis. 68(8):1247-54
57. Moss RB,Milla C, Colombo J, Accurso F, Zeitlin PL, et al. 2007. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A randomized placebo-controlled phase 2B trial. Hum. Gene Ther. 18(8):726-32
58. Kotin RM. 2011. Large-scale recombinant adeno-Associated virus production. Hum. Mol. Genet. 20(R1):R2-6
59. Xiao X, Li J, Samulski RJ. 1996. Efficient long-term gene transfer intomuscle tissue of immunocompetent mice by adeno-Associated virus vector. J. Virol. 70(11):8098-108
60. NakaiH, Storm TA, Kay MA. 2000. Recruitment of single-stranded recombinant adeno-Associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J. Virol. 74(20):9451-63
61. McCarty DM, Young SM, Samulski RJ. 2004. Integration of adeno-Associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38:819-45
62. Kaeppel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, et al. 2013. A largely random AAV integration profile after LPLD gene therapy. Nat. Med. 19(7):889-91
63. Tatsis N, Ertl HCJ. 2004. Adenoviruses as vaccine vectors. Mol. Ther. 10(4):616-29
64. Alba R, Bosch A, Chillon M. 2005. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 12(Suppl. 1):S18-27
65. Stilwell JL, Samulski RJ. 2004. Role of viral vectors and virion shells in cellular gene expression. Mol. Ther. 9(3):337-46
66. Manservigi R, Argnani R, Marconi P. 2010. HSV recombinant vectors for gene therapy. Open Virol. J. 4:123-56
67. Smith GL, Law M. 2004. The exit of vaccinia virus from infected cells. Virus Res. 106(2):189-97
68. Gnant MFX, Noll LA, Irvine KR, Puhlmann M, Terrill RE, et al. 1999. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbitmodel of liver metastases. J. Natl. Cancer Inst. 91(20):1744-50
69. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, et al. 2011. Intravenous delivery of a multimechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7362):99-102
70. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, et al. 2013. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19(3):329-36
71. Park B-H, Hwang T, LiuT-C, Sze DY, Kim J-S, et al. 2008. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol. 9(6):533-42
72. Cartier N, Aubourg P. 2010. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol. 20(4):857-62
73. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, et al. 2013. Lentiviral hematopoietic stem cell gene therapy in patients withWiskott-Aldrich syndrome. Science 341(6148):1233151
74. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, et al. 2013. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341(6148):1233158
75. Porter DL, Levine BL, Kalos M, Bagg A, June CH. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8):725-33
76. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95):95ra73
77. Brentjens RJ, Rivière I, Park JH, Davila ML,Wang X, et al. 2011. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18):4817-28
78. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, et al. 2013. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5(177):177ra38
79. Stroes ES, Nierman MC,Meulenberg JJ, Franssen R, Twisk J, et al. 2008. Intramuscular administration of AAV1-lipoprotein lipaseS447x lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 28(12):2303-4
80. GaudetD, deWal J, Tremblay K,Déry S, van Deventer S, et al. 2010. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler. Suppl. 11(1):55-60
81. Carpentier AC, Frisch F, Labbé SM, Gagnon R, de Wal J, et al. 2012. Effect of alipogene tiparvovec (AAV1-LPLS447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab. 97(5):1635-44
82. Maguire A, Simonelli F. 2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358(21):2240-48
83. Maguire AM,High KA, Auricchio A, Wright JF, Pierce EA, et al. 2009. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374(9701):1597-605
84. Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, et al. 2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358(21):2231-39
85. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, et al. 2012. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol. 130(1):9-24
86. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, et al. 2012. AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med. 4(120):120ra15
87. MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, et al. 2014. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 6736(13):2117-20
88. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, et al. 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101(8):2963-72
89. Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, et al. 2011. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365(25):2357-65
90. Bowles DE, McPhee SWJ, Li C, Gray SJ, Samulski JJ, et al. 2012. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20(2):443-55
91. McPhee SWJ, Janson CG, Li C, Samulski RJ, Camp AS, et al. 2006. Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med. 8(5):577-88
92. Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, et al. 2006. Phase I trial of intramuscular injection of a recombinant adeno-Associated virus serotype 2 l-Antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 17(12):1177-86
93. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, et al. 2011. Phase 2 clinical trial of a recombinant adeno-Associated viral vector expressing 1-Antitrypsin: interim results. Hum. Gene Ther. 22(10):1239-47
94. Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, et al. 2010. Sustained-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol. 68(5):629-38
95. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, et al. 2009. Limb-girdle muscular dystrophy type 2D gene therapy restores-sarcoglycan and associated proteins. Ann. Neurol. 66(3):290-97
96. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, et al. 2009. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J. Card. Fail. 15(3):171-81
97. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, et al. 2011. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124(3):304-13
98. Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, et al. 2011. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci. Transl. Med. 3(92):92ra64
99. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, et al. 2007. Safety and tolerability of gene therapy with an adeno-Associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369(9579):2097-105
100. LeWitt PA,Rezai AR, Leehey MA,Ojemann SG, Flaherty AW, et al. 2011. AAV2-GADgene therapy for advanced Parkinson's disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10(4):309-19
101. Marks WJ, Ostrem JL, Verhagen L, Starr PA, Larson PS, et al. 2008. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-Associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol. 7(5):400-8
102. Christine CW, Starr PA, Larson PS, Vanbrocklin HF, Bankiewicz KS, Aminoff MJ. 2009. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73(20):1662-69
103. Muramatsu S, FujimotoK,Kato S,Mizukami H, Asari S, et al. 2010. A phase I study of aromatic L-Amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 18(9):1731-35
104. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80(1-2):148-58
105. Smaill F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, et al. 2013. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-Adenovirus immunity. Sci. Transl. Med. 5(205):205ra134
106. Hill AVS, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, et al. 2010. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccines 6(1):78-83
107. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. 2008. HIV-1 vaccine-induced immunity in the test-of-concept step study: A case-cohort analysis. Lancet 372(9653):1894-905
108. Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, et al. 2009. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin. Vaccine Immunol. 16(9):1285-92
109. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 372(9653):1881-93
110. Scallan CD, Tingley DW, Lindbloom JD, Toomey JS, Tucker SN. 2013. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin. Vaccine Immunol. 20(1):85-94
111. Peters W, Brandl JR, Lindbloom JD, Martinez CJ, Scallan CD, et al. 2013. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-T cell responses in humans. Vaccine 31(13):1752-58
112. Aguilar LK, Guzik BW, Aguilar-Cordova E. 2011. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J. Cell. Biochem. 112(8):1969-77
113. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, et al. 2000. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 60(22):6359-66
114. Mastrangelo MJ, Maguire HC, Eisenlohr LC, Laughlin CE, Monken CE, et al. 1998. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6(5):409-22
115. J. Gene Med. 2013. Gene Therapy Clinical Trials Worldwide, 2013, retrieved September 14, 2014. http:// www.abedia.com/wiley/
116. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, et al. 2010. Prevalence of serum IgG and neutralizing factors against adeno-Associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21(6):704-12
117. Liu Q, Huang W, Zhang H,Wang Y, Zhao J, et al. 2014. Neutralizing antibodies against AAV2, AAV5 AND AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther. 21(8):732-38
118. Cottard V, Valvason C, Falgarone G, Lutomski D, Boissier M-C, Bessis N. 2004. Immune response against gene therapy vectors: influence of synovial fluid on adeno-Associated virusmediated gene transfer to chondrocytes. J. Clin. Immunol. 24(2):162-69
119. Boissier M-C, Lemeiter D, Clavel C, Valvason C, Laroche L, et al. 2007. Synoviocyte infection with adeno-Associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype. Hum. Gene Ther. 18(6):525-35
120. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Bringas JR, et al. 2013. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 24(5):526-32
121. Kotterman MA, Yin L, Strazzeri JM, Flannery JG, MeriganWH, Schaffer DV. 2015. Antibody neutralization poses a barrier to intravitreal adeno-Associated viral vector gene delivery to non-human primates. Gene Ther. 22(2):116-26
122. Lim K, Klimczak R, Yu JH, Schaffer DV. 2010. Specific insertions of zinc finger domains into Gag-Pol yield engineered retroviral vectors with selective integration properties. PNAS 107(28):12475-80
123. Yáñez-Muñoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, et al. 2006. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12(3):348-53
124. Kotterman MA, Schaffer DV. 2014. Engineering adeno-Associated viruses for clinical gene therapy. Nat. Rev. Genet. 15:445-51
125. Bartel M, Schaffer D, Büning H. 2011. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front. Microbiol. 2:204
126. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, et al. 2000. Epitope mapping of human anti-Adeno-Associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74(4):1761-66
127. Wobus CE, Hügle-Dörr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. 2000. Monoclonal antibodies against the adeno-Associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74(19):9281-93
128. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, et al. 2006. Mutations on the external surfaces of adeno-Associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80(2):821-34
129. Mingozzi F, Anguela XM, PavaniG, Chen Y,Davidson RJ, et al. 2013. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5(194):194ra92
130. Zhong L, Li B,Mah CS,Govindasamy L, Agbandje-McKenna M, et al. 2008. Next generation of adenoassociated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. PNAS 105(22):7827-32
131. Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, et al. 2008. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381(2):194-202
132. Shen S, Horowitz ED, Troupes AN, Brown SM, Pulicherla N, et al. 2013. Engraftment of a galactose receptor footprint onto adeno-Associated viral capsids improves transduction efficiency. J. Biol. Chem. 288(40):28814-23
133. Perabo L, Endell J, King S, Lux K, Goldnau D, et al. 2006. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-Associated virus. J. Gene Med. 8(2):155-62
134. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. 2006. Directed evolution of adeno-Associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24(2):198-204
135. Bartel MA, Hwang B-Y, Stone D, Koerber JT, Couto L, et al. 2012. Directed evolution of AAV for enhanced evasion of human neutralizing antibodies. Mol. Ther. 20(Suppl. 1):S140 (Abstr.)
136. Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV. 2009. A novel adeno-Associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLOS ONE 4(10):e7467
137. Koerber JT, Klimczak R, Jang J-H, Dalkara D, Flannery JG, Schaffer DV. 2009. Molecular evolution of adeno-Associated virus for enhanced glial gene delivery. Mol. Ther. 17(12):2088-95
138. Excoffon KJD, Koerber JT, Dickey DD, Murtha M, Keshavjee S, et al. 2009. Directed evolution of adeno-Associated virus to an infectious respiratory virus. PNAS 106(10):3865-70
139. Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, et al. 2009. A myocardium tropic adenoassociated virus (AAV) evolved by DNA shuffling and in vivo selection. PNAS 106(10):3946-51
140. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, et al. 2010. Reengineering a receptor footprint of adeno-Associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 28(1):79-82
141. Jang J-H, Koerber JT, Kim J-S, Asuri P, Vazin T, et al. 2011. An evolved adeno-Associated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol. Ther. 19(4):667-75
142. Asuri P, Bartel MA, Vazin T, Jang J-H, Wong TB, Schaffer DV. 2012. Directed evolution of adenoassociated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol. Ther. 20(2):329-38
143. Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, et al. 2010. Directed evolution of a novel adeno-Associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18(3):570-78
144. Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, et al. 2013. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506:382-86
145. Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, et al. 2013. In vivo-directed evolution of a new adeno-Associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med. 5(189):189ra76
146. Brown BD, Naldini L. 2009. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 10(8):578-85
147. Holt N, Wang J, Kim K, FriedmanG,Wang X, et al. 2010. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28(8):839-47
148. Tang W, Lalezari J, June C, Tebas P, Lee G, et al. 2012. Increases in CD4 counts and effects on HIV in aviremic HIV-infected subjects infused with zinc finger nuclease (ZFN) CCR5 modified autologous CD4 T-cells (SB-728-T). Mol. Ther. 20(Suppl. 1):S21-22 (Abstr.)
149. Lee GK, Zeidan J, Lalezari J,Mitsuyasu R, Wang S, et al. 2013. Long term CD4 reconstitution in HIV subjects receiving ZFN CCR5 modified CD4 T-cells (SB-728-T) may be attributed to the sustained durability of the central memory T-cell subset. Mol. Ther. 21(Suppl. 1):S24 (Abstr.)
150. Russell DW, Hirata RK. 1998. Human gene targeting by viral vectors. Nat. Genet. 18(4):325-30
151. Li H, Haurigot V, Doyon Y, Li T, Wong SY, et al. 2011. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475(7355):217-21
152. Gaj T, Gersbach CA, Barbas CF. 2013. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31(7):397-405